Today Idera has a rich pipeline of TLR-targeted drug candidates that span a broad range of therapeutic applications. This achievement is due to our unwavering focus on applying nucleic acid chemistry expertise to create new drugs, beginning with our pioneering antisense research nearly two decades ago. We have translated the knowledge from our early efforts in antisense technology to create the TLR-targeted drugs that are now demonstrating great potential. As Idera scientists have learned more about TLR biology we are recognizing the added potential of antisense technology to modify immune responses. As always, Idera is committed to improving the lives of patients through a science-driven approach to the creation of new medicines.